AbbVie Inc (ABBV)vsLENSAR Inc (LNSR)
ABBV
AbbVie Inc
$290.89
+1.68%
HEALTHCARE · Cap: $504.37B
LNSR
LENSAR Inc
$5.97
+0.84%
HEALTHCARE · Cap: $74.58M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 106740% more annual revenue ($64.39B vs $60.26M). LNSR leads profitability with a 57.6% profit margin vs 9.8%. LNSR trades at a lower P/E of 33.7x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
LNSR
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Margin of Safety
-85.9%
Fair Value
$6.68
Current Price
$5.97
$0.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 36 in profit
Keeps 58 of every $100 in revenue as profit
Conservative balance sheet, low leverage
18.4% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 57.6% and operating margin at 12.9%. Revenue growth of 18.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : LNSR
The primary concerns for LNSR are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while LNSR is a growth play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.95 — expect wider price swings.
LNSR is growing revenue faster at 18.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 56/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?